The Sputnik V vaccine for COVID-19, developed through the National Research Institute for Gamaleya Epidemiology and Microbiology in Russia, has been shown to be 92% effective.
The confirmation is based on the first intermediate knowledge of Russia’s largest randomized placebo-controlled Phase III clinical trials involving 40,000 volunteers, according to a press release from Gamaleya and the Russian Direct Investment Fund (DRIF).
Trials evaluated efficacy in more than 16,000 volunteers who won the vaccine or placebo 21 days after the first injection.
In September 2020, Dr. Reddy’s and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, partnered to conduct trials on the Sputnik V vaccine and its distribution in India.
On 11 August 2020, the Sputnik V vaccine was registered through the Russian Ministry of Health and became the world’s first registered vaccine opposed to COVID-19 founded on the human adenovial vector platform.
In September, the vaccine was first given to a volunteer organization in the “red zones” of Russian hospitals.
That of another 10,000 vaccinated volunteers, representing doctors and other high-risk equipment under civilian use of the open-air vaccine in clinical trials, also showed a vaccine effectiveness rate of more than 90%.
As of November 11, from clinical trials in the 29 Russian medical centers, more than 20,000 volunteers were vaccinated with the first dose and more than 16,000 volunteers with the first and last doses of the vaccine.
In addition, to date, no adverse occasions were known as a component of the search.
Some of those vaccinated had minor short-term effects, such as injection site pain, influenza syndrome, fever, weakness, fatigue, and headache.
With higher production at new production sites, the Sputnik V vaccine will soon be available to a wider population, he said.
“This will break the existing trend and lead to a imaginable minimisation of COVID-19 infection rates, first in Russia and then in the world,” he said.
Pfizer Inc and BioNTech SE said Monday that their vaccine candidate is more than 90% effective at preventing COVID-19.
Edited through Suman Singh